|
 |
International Conference on Alzheimer's Disease
The International Conference on Alzheimer's Disease (ICAD) is taking place in Chicago from July 26 to July 31. More than 5,000 researchers, physicians and care providers from 60 countries are convening to discuss topics involving a broad range of research and caregiving. Overall there will be more than 2,000 sessions and workshops. Many of the articles in today's news cover these sessions and press releases.
A Link to Maternal Alzheimer's Disease
(Source: ICAD/Newswise) - According to new findings, a maternal history of Alzheimer's appears to predispose individuals to the disease because their brains aren't using glucose efficiently.
Alzheimer's Treatment Shows Promise in Clinical Trials
(Source: MIT) - Researchers at MIT report promising outcomes for a a nutrient-rich drink which may offer a new option in the management of patients with mild Alzheimer's disease.
Family History May Reveal Clues to Alzheimer's Risk
(Source: DukeHealth) - Duke University researchers report that family histories focusing on the APOE genes do not provide a complete picture of overall Alzheimer's risk.
Multiple Imaging Methods Provide Details about Cognitive Impairment
(Source: ICAD/Mayo Clinic) - Two new studies found that imaging methods like magnetic resonance imaging (MRI), magnetic resonance (MR) spectroscopy, and 11C Pittsburgh Compound B (11C-PIB) each provide independently valuable information about cognitive function. By using all of these imaging methods together, physicians can better predict the likelihood of a patients' progression to Alzheimer's disease.
Stroke May Lead To Mild Cognitive Impairment
(Source: ICAD/Mayo Clinic) - A new Mayo Clinic study found that people with a history of strokes had a greater likelihood of developing mild cognitive impairment, a disorder of the brain that affects memory and thinking abilities.
Improved Estrogen Reception May Sharpen Fuzzy Memory
(Source: University of Florida ) - Researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Alzheimer's Drug Data Unclear
(Source: ICAD/ WSJ) - Elan Corp. and Wyeth presented complete data from the midstage trial of their experimental drug bapineuzumab for Alzheimer's disease, and said the results support an earlier decision to move it into more-advanced studies before a thorough assessment had been made.
Blood and Spinal Fluid Markers for Early Alzheimer's Detection
(Source: ICAD/Alzheimer's Association) - Studies shed new light on early detection of Alzheimer's disease with advances in biomarkers.
Studies of Potential New Treatments for Alzheimer's
(Source: ICAD/Alzheimer's Associaiton) - Results of four studies of potential new treatments for Alzheimer's - even an unsuccessful late stage clinical trial - increase the field's knowledge and point scientists toward advances in therapies for the disease.
Results of Once-Daily Extended-Release Namenda Study
(Source: Forest Laboratories) - Forest Laboratories reported positive results of a Phase III study of a once-daily extended-release formulation of the company's Alzheimer's treatment, Namenda (memantine HCl).
|
|